Accelerating Cancer Trials with Digital Twins
Leveraging artificial intelligence to generate digital twins that accelerate cancer trials.
Modern medical advancements and novel drugs have the potential to drastically improve outcomes for patients during treatments for various forms of cancer. Unfortunately, these treatment options are often delayed due to a long and cumbersome trial process.
How We Are Solving It
The Accelerating Cancer Trials with Digital Twins project aims to reduce the prohibitive time, cost and failure rate associated with bringing novel, effective anti-cancer drugs to market. Led by Altis Labs, Inc., the consortium is creating and incorporating digital twin models in cancer trials to facilitate earlier and more accurate measurements of drug efficacy that can be used within a created software platform to provide more accurate and cost effective clinical trials and better treatment decisions for individual cancer patients.
Canadian cancer centers will benefit from their fragmented clinical data being curated into the world’s largest and richest cancer imaging dataset, which will attract leading researchers and result in significant new IP, as well as high-impact publications. They will further benefit from Altis’ commercialization of digital twin software through negotiated licensing terms. Additionally, oncologists will gain access to novel technologies to inform treatment decisions and Canadian cancer patients will benefit from personalized care and novel, efficacious treatments.